Igor Shilovskiy

Dr. Igor Shilovskiy

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Immunity
Verified
Journal Article
Closed access
ODOxana Dmitrieva-Posocco
Oxana Dmitrieva-Posocco
ADAmiran Dzutsev
Amiran Dzutsev
DPDavid F. Posocco
David F. Posocco
VHVivianty Hou
Vivianty Hou
WYWuxing Yuan
Wuxing Yuan
SGSergei I. Grivennikov
Sergei I. Grivennikov

16 February 2016 in Biochemistry (Moscow)
Verified
Journal Article
Closed access
PDF file
ODO. S. Dmitrieva
O. S. Dmitrieva
ISIgor Shilovskiy
Igor Shilovskiy
MKM. R. Khaitov
M. R. Khaitov
SGS. I. Grivennikov
S. I. Grivennikov
The idea of a potential link between cancer and inflammation was first proposed by R. Virchow in the nineteenth century. However, clear evidence regarding a key role of inflammation in oncogenesis appeared only during the last decade. Now the tumor microenvironment is commonly considered as an obligatory and significant component of almost all types of cancer, and the cells infiltrating such microenvironment are a source of inflammatory cytokines. Such cytokines play a key role in regulating inflammation during both normal immune response and developing cancer. In this review, we explore the role of two inflammatory cytokines interleukin 1 and interleukin 6 in cancer development. These cytokines have pleiotropic effects on various cell types in the tumor microenvironment, particularly being able to regulate pro-oncogenic transcription factors NF-κB and STAT3. For this reason, such cytokines influence key parameters of oncogenesis, increasing cell resistance to apoptosis, proliferation of cancer cells, angiogenesis, invasion and malignancy as well as the ability of tumor cells to respond to anticancer therapy. Here we summarize novel experimental data regarding mechanisms underlying the interaction between chronic inflammation and malignant neoplasms.

6 April 2020 in Allergy
Verified
Journal Article
Open access
PDF file
YDYulia Dorofeeva
Yulia Dorofeeva
ISIgor Shilovskiy
Igor Shilovskiy
ITInna Tulaeva
Inna Tulaeva
MFMargarete Focke-Tejkl
Margarete Focke-Tejkl
SFSabine Flicker
Sabine Flicker
RVRudolf Valenta
Rudolf Valenta
Allergen‐specific immunotherapy (AIT) is an allergen‐specific form of treatment for patients suffering from immunoglobulin E (IgE)‐associated allergy; the most common and important immunologically mediated hypersensitivity disease. AIT is based on the administration of the disease‐causing allergen with the goal to induce a protective immunity consisting of allergen‐specific blocking IgG antibodies and alterations of the cellular immune response so that the patient can tolerate allergen contact. Major advantages of AIT over all other existing treatments for allergy are that AIT induces a long‐lasting protection and prevents the progression of disease to severe manifestations. AIT is cost effective because it uses the patient´s own immune system for protection and potentially can be used as a preventive treatment. However, broad application of AIT is limited by mainly technical issues such as the quality of allergen preparations and the risk of inducing side effects which results in extremely cumbersome treatment schedules reducing patient´s compliance. In this article we review progress in AIT made from its beginning and provide an overview of the state of the art, the needs for further development, and possible technical solutions available through molecular allergology. Finally, we consider visions for AIT development towards prophylactic application.

10 April 2021 in Allergy
Verified
Journal Article
Closed access
PDF file
MKMusa Khaitov
Musa Khaitov
ANAlexandra Nikonova
Alexandra Nikonova
ISIgor Shilovskiy
Igor Shilovskiy
KKKsenia Kozhikhova
Ksenia Kozhikhova
IKIlya Kofiadi
Ilya Kofiadi
VSVeronica Skvortsova
Veronica Skvortsova

19 July 2017 in Allergy
Verified
Journal Article
Open access
PDF file
MEM. R. Edwards
M. R. Edwards
RWR. P. Walton
R. P. Walton
DJD. J. Jackson
D. J. Jackson
WFW. Feleszko
W. Feleszko
CSC. Skevaki
C. Skevaki
EFEaaci Anti‐Infectives In Asthma And Asthma Exacerbations Task Force
Eaaci Anti‐Infectives In Asthma And Asthma Exacerbations Task Force
Asthma is responsible for approximately 25,000 deaths annually in Europe despite available medicines that maintain asthma control and reduce asthma exacerbations. Better treatments are urgently needed for the control of chronic asthma and reduction in asthma exacerbations, the major cause of asthma mortality. Much research spanning >20 years shows a strong association between microorganisms including pathogens in asthma onset, severity and exacerbation, yet with the exception of antibiotics, few treatments are available that specifically target the offending pathogens. Recent insights into the microbiome suggest that modulating commensal organisms within the gut or lung may also be a possible way to treat/prevent asthma. The European Academy of Allergy & Clinical Immunology Task Force on Anti‐infectives in Asthma was initiated to investigate the potential of anti‐infectives and immunomodulators in asthma. This review provides a concise summary of the current literature and aimed to identify and address key questions that concern the use of anti‐infectives and both microbe‐ and host‐based immunomodulators and their feasibility for use in asthma.

13 September 2023 in Allergy
Verified
Journal Article
Open access
GBGeorgii Brazhnikov
Georgii Brazhnikov
ESEvgenii Smolnikov
Evgenii Smolnikov
ALAlla Litovkina
Alla Litovkina
TJTianchi Jiang
Tianchi Jiang
ASArtem Shatilov
Artem Shatilov
RCRaffaela A. Campana
Raffaela A. Campana
Background: The nature of epitopes on Bet v 1 recognized by natural IgG antibodies of birch pollen allergic patients and birch pollen‐exposed but non‐sensitized subjects has not been studied in detail.Objective: To investigate IgE and IgG recognition of Bet v 1 and to study the effects of natural Bet v 1‐specific IgG antibodies on IgE recognition of Bet v 1 and Bet v 1‐induced basophil activation.Methods: Sera from birch pollen allergic patients (BPA, n = 76), allergic patients without birch pollen allergy (NBPA, n = 40) and non‐allergic individuals (NA, n = 48) were tested for IgE, IgG as well as IgG1 and IgG4 reactivity to folded recombinant Bet v 1, two unfolded recombinant Bet v 1 fragments comprising the N‐terminal (F1) and C‐terminal half of Bet v 1 (F2) and unfolded peptides spanning the corresponding sequences of Bet v 1 and the apple allergen Mal d 1 by ELISA or micro‐array analysis. The ability of Bet v 1‐specific serum antibodies from non‐allergic subjects to inhibit allergic patients IgE or IgG binding to rBet v 1 or to unfolded Bet v 1‐derivatives was assessed by competition ELISAs. Furthermore, the ability of serum antibodies from allergic and non‐allergic subjects to modulate Bet v 1‐induced basophil activation was investigated using rat basophilic leukaemia cells expressing the human FcεRI which had been loaded with IgE from BPA patients.Results: IgE antibodies from BPA patients react almost exclusively with conformational epitopes whereas IgG, IgG1 and IgG4 antibodies from BPA, NBPA and NA subjects recognize mainly unfolded and sequential epitopes. IgG competition studies show that IgG specific for unfolded/sequential Bet v 1 epitopes is not inhibited by folded Bet v 1 and hence the latter seem to represent cryptic epitopes. IgG reactivity to Bet v 1 peptides did not correlate with IgG reactivity to the corresponding Mal d 1 peptides and therefore does not seem to be a result of primary sensitization to PR10 allergen‐containing food. Natural Bet v 1‐specific IgG antibodies inhibited IgE binding to Bet v 1 only poorly and could even enhance Bet v 1‐specific basophil activation.Conclusion: IgE and IgG antibodies from BPA patients and birch pollen‐exposed non‐sensitized subjects recognize different epitopes. These findings explain why natural allergen‐specific IgG do not protect against allergic symptoms and suggest that allergen‐specific IgE and IgG have different clonal origin.